42359
document
Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders : Part A -- medical results . BACKGROUND This study investigated the effect of oral dimercapto succinic acid ( DMSA ) therapy for children with autism spectrum disorders ages 3-8 years . METHODS Phase 1 involved 65 children who received one round of DMSA ( 3 days ) . Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2 . In phase 2 , 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo . RESULTS DMSA greatly increased the excretion of lead , substantially increased excretion of tin and bismuth , and somewhat increased the excretion of thallium , mercury , antimony , and tungsten . There was some increase in urinary excretion of essential minerals , especially potassium and chromium . The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases , and greatly improved abnormal platelet counts , suggesting a significant decrease in inflammation . CONCLUSION Overall , DMSA therapy seems to be reasonably safe , effective in removing several toxic metals ( especially lead ) , dramatically effective in normalizing RBC glutathione , and effective in normalizing platelet counts . Only 1 round ( 3 days ) was sufficient to improve glutathione and platelets . Additional rounds increased excretion of toxic metals .
42360
Intervention_Pharmacological
DMSA
42361
Intervention_Physical
therapy
42362
Intervention_Pharmacological
oral dimercapto succinic acid ( DMSA )
42363
Intervention_Pharmacological
DMSA
42364
Intervention_Pharmacological
DMSA
42365
Intervention_Control
placebo
42366
Intervention_Pharmacological
DMSA
42367
Intervention_Pharmacological
DMSA
42368
Outcome_Other
Safety and efficacy
42369
Outcome_Physical
excretion of lead
42370
Outcome_Physical
excretion of tin and bismuth
42371
Outcome_Physical
excretion of thallium , mercury , antimony , and tungsten
42372
Outcome_Physical
urinary excretion of essential minerals
42373
Outcome_Physical
normalization of RBC glutathione
42374
Outcome_Physical
abnormal platelet counts
42375
Outcome_Physical
inflammation
42376
Outcome_Other
safe , effective
42377
Outcome_Physical
toxic metals
42378
Outcome_Physical
normalizing RBC glutathione
42379
Outcome_Physical
normalizing platelet counts
42380
Outcome_Physical
glutathione and platelets
42381
Outcome_Physical
excretion of toxic metals
42382
Participant_Age
children
42383
Participant_Condition
autism spectrum disorders
42384
Participant_Age
children
42385
Participant_Condition
autism spectrum
42386
Participant_Age
3-8 years
42387
Participant_Sample-size
65
42388
Participant_Age
children
42389
Participant_Condition
high urinary excretion of toxic metals
42390
Participant_Sample-size
2 , 49